NCT07588984Not yet recruiting
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study
GLP-1 Medication & Behavioral Health on Weight and Metabolic Outcomes: FLOURISH (Functional Longitudinal Outcomes Under Intentional Small Habits) & THRIVE (Trajectories of Health, Resilience & Integrated Vitality Evaluation) Cohort Study
Source: ClinicalTrials.gov · Last updated 15 May 2026
Brief summary (registry, in English)
This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health indicators, and program engagement. FLOURISH is a 6-arm prospective cohort study comparing an Education-only control, Noom Weight, standard-dose compounded semaglutide, microdose compounded semaglutide, standard-dose tirzepatide (Noom Plus), and microdose tirzepatide (Noom Plus Microdose). THRIVE is a nested 2-arm prospective study comparing a Proactive Health program to a Noom Free Tier control. Participants complete monthly surveys, remote biomarker collection (Tasso device), connected-scale weigh-ins, and in-app biometric assessments (FaceScan, BodyScan). Microdose and Free Tier arms also use wearable fitness trackers. Primary outcomes are changes in cardiometabolic biomarkers, weight, body composition, and GLP-1 side effect profile. Total N = 2,310; 24-month duration.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 2310 (estimated)
- First submitted
- 30 Apr 2026
- Start date
- 30 Apr 2026
- Primary completion date
- May 2029
- Lead sponsor
- Noom Inc.
- Diseases
- Obesity
- NCT number
- NCT07588984
What you commit to
- Study type: Observational
- Planned participants: 2310
- From 30 Apr 2026 to the primary completion date, May 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- GLP-1 use in the last 24 weeks (prior to Noom program enrollment if in GLP-1 arm)
- Previous or planned (during the 12-month study) bariatric surgery
- Currently taking a medication known to cause weight gain (e.g., antipsychotics, antidepressants, diabetes medication, or corticosteroids)
- Depression screen results in a PHQ-8 score of 20 or greater.
- All medicated arms and Noom Weight arms (only):
- \- Purchased more than the base Noom program offered for participant's specific arm
- GLP-1 Medication Arms Only:
Other illness
- Active eating disorder
- Active cancer
- Type 1 diabetes or current Insulin use
- Personal or family history of medullary thyroid cancer
- Personal or family history of Multiple Endocrine Neoplasia Type 2 (MEN2)
- Personal history of Pancreatitis
Other
- Study screener completed more than 11 days after Noom program enrollment if participating in a Noom program (GLP-1 programs, Noom Weight, and Free Tier)
- Female who is pregnant, breast-feeding, or intends to become pregnant during the 12-month program
- GLP-1 agonist use is contraindicated (per program criteria) in members with:
Who the study is looking for
- Speaks English
- Community-dwelling, community-living status
- Able to ambulate independently, with or without aids or devices
- Unless medically indicated, willingness to stay on current program for 12 months and participate in all study activities
- Provides informed consent for study participation
- Commitment and willingness to participate, as assessed by completion of decisional balance exercise
- Program-specific eligibility:
- Medication arms only: Meets standard of care program enrollment criteria for GLP-1 medication. Did not add other products or programs to Noom subscription.
- Noom Weight only: Individual who is not interested in medication
- Education-only Control Group: Individual who is interested in weight loss who is not currently enrolled in a structured weight loss program or medication program and does not intend to for the duration of the study Free Tier only: Willingness to use Free Tier
Age in the registry: 18 years to 64 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Noom, Inc. Coordinator of this site? Confirm its status | Princeton | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.